Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OLDIAS

Financiado

Cerrado

Online Dialysis Sensor

End-stage renal disease (ESRD) is the most severe form of chronic kidney disease that is an incurable health failure. ESRD is a widespread health issue in developed countries and the patients have only two options: either receive... ver más

31/08/2015

OPTOFLUID TECHNOLO...

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

OPTOFLUID TECHNOLOGIES O No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2015-08-31

PHC-12-2014-1: Clinical research for the validatio...

I+D

Cerrada hace 10 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

OPTOFLUID TECHNOLOGIES O

50.00K€ | Lider

Proyectos interesantes

OLDIAS2

Medical Technol...

Data Science

3M€ Cerrado

RBM-Screen

Medical Technol...

Data Science

71K€ Cerrado

ablute_

Medical Technol...

Data Science

75K€ Cerrado

ReTeBESKO

Medical Technol...

Data Science

238K€ Cerrado

NEPHRON+

Medical Technol...

Data Science

7M€ Cerrado

BEAt-DKD

Medical Technol...

Data Science

31M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 6 meses Fecha Inicio: 2015-02-26
Fecha Fin: 2015-08-31

Líder del proyecto

OPTOFLUID TECHNOLOGIES O No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto End-stage renal disease (ESRD) is the most severe form of chronic kidney disease that is an incurable health failure. ESRD is a widespread health issue in developed countries and the patients have only two options: either receive permanent renal replacement therapy or undergo surgery to receive a kidney transplant. There are approximately 3.1 million patients worldwide suffering from ESRD that need artificial methods to replace regular kidney functions in their organism. The main objective of the project is to validate the uremic biomarkers in a clinical research setting by developing a diagnostic medical device in the form of a novel on-line dialysis sensor that offers a unique method for the biomarker detection. At the heart of the development is technology developed by Optofluid Technologies (OFT) that is free of the flaws of current dialysis monitoring methods such as estimating only urea based biomarkers and will offer enhanced possibilities for dialysis monitoring and quality assessment. This enables the developed sensor to outperform all the current monitoring methods on the market and fully utilize the possibilities of modern dialysis methods resulting in higher treatment efficiency and ultimately disrupting the dialysis equipment market and replacing previous technologies. The market demand has been proven by attracting business inquiries from the leading dialysis equipment producers. Negotiations with selected partners are underway. A successful commercialization will help to improve clinical decisions by clinicians leading to better treatment. Besides enhanced treatment quality, the novel OFT´s technology will significantly reduce the environmental impact of the treatment, reduce the healthcare costs of ESRD patients and improve the patients’ life-quality. In order to guarantee a successful commercialization OFT has a team of experts with previous experience in business development and medical technology.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores